Drug intelligence / Profile preview

SL-172154 + mirvetuximab soravtansine

Development stage: Unknown
Lead developer: Shattuck Labs
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**SL-172154 + mirvetuximab soravtansine** is an investigational combination therapy under clinical evaluation for the treatment of platinum-resistant ovarian cancer. SL-172154 is a bifunctional fusion protein that simultaneously inhibits the CD47/SIRPα checkpoint to enhance phagocytosis and activates the CD40 receptor to stimulate antigen-presenting cells and boost antitumor immunity. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), delivering a cytotoxic maytansinoid payload to kill tumor cells. The combination is being studied for synergistic effects in activating immune responses and direct tumor cell killing[2][3][4].

Brand names: Elahere
Other names: SIRPα-Fc-CD40L + mirvetuximab soravtansine

Targets

CD47 (Cluster of Differentiation 47)SIRPA (Signal-regulatory protein alpha)FOLR1 (FRα)CD40 (Cluster of differentiation 40 receptor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SL-172154 + mirvetuximab soravtansine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL-172154 + mirvetuximab soravtansine.

Explore the full profile